Neoadjuvant chemotherapy for operable breast cancer

British Journal of Surgery

Volumn 94, Issue 10, 2007, Pages 1189-1200

  Mieog, J S D ^a   Van Der Hage, J A ^a   Van De Velde, C J H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MASTECTOMY; META ANALYSIS; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; SURVIVAL ANALYSIS;

EID: 35348877159     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.5894     Document Type: Article

References (37)

1. Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 2003; 21: 2600-2608.
2. Kiebert GM, de Haes JC, van de Velde CJ. The impact of breast-conserving treatment and mastectomy on the quality of life of early-stage breast cancer patients: a review. J Clin Oncol 1991; 9: 1059-1070.
3. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005; 97: 188-194.
4. McAuley L, Pham B, Tugwell P, Moher D. Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses? Lancet 2000; 356: 1228-1231.
5. Williamson PR, Smith CT, Hutton JL, Marson AG. Aggregate data meta-analysis with time-to-event outcomes. Stat Med 2002; 21: 3337-3351.
6. Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions 4.2.6. In The Cochrane Library, Issue 4. John Wiley: Chichester, 2006.
7. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815-2834.
8. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335-371.
9. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
10. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In Systematic Reviews in Health Care: Meta-Analysis in Context (2nd edn), Egger M, Davey Smith G, Altman DG (eds). BMJ Publication Group: London, 2001; 285-312.
11. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
12. Jakesz R. Comparison of pre- vs. postoperative chemotherapy in breast cancer patients: four-year results of Austrian Breast & Colorectal Cancer Study Group (ABCSG) Trial 7. J Clin Oncol (Meeting Abstracts) 2001; 20: Abstract 125.
13. Mauriac L, MacGrogan G, Avril A, Durand M, Floquet A, Debled M et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Group Sein (IBBGS). Ann Oncol 1999; 10: 47-52.
14. Gianni L, Baselga J, Eiermann W, Guillem Porta V, Semiglazov V, Lluch A et al. European Cooperative Trial in Operable Breast Cancer (ECTO): improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF). J Clin Oncol (Meeting Abstracts) 2005; 23: 513 (Abstract).
15. Forouhi P, Dixon JM, Leonard RCF, Chetty U. Prospective randomized study of surgical morbidity following primary systemic therapy for breast cancer. Br J Surg 1995; 82: 79-82.
16. van der Hage JA, van de Velde CJH, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001; 19: 4224-4237.
17. Scholl SM, Asselain B, Palangie T, Dorval T, Jouve M, Garcia Giralt E et al. Neoadjuvant chemotherapy in operable breast cancer. Eur J Cancer 1991; 27: 1668-1671.
18. Broet P, Scholl SM, de la Rochefordiere A, Fourquet A, Moreau T, De Rycke Y et al. Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial. Breast Cancer Res Treat 1999; 58: 151-156.
19. Enomoto K, Ikeda T, Matsui A, Kitajima M, Koh J, Masamura S et al. Neoadjuvant therapy in stage II with T > = 4CM and stage III breast cancer. Eur J Cancer 1998; 34(Suppl 1): 33 (Abstract).
20. Ostapenko V, Pipiriene T, Valuckas K. Primary chemotherapy in conservative treatment of stage II breast cancer. Eur J Cancer 1998; 34(Suppl 1): 34 (Abstract).
21. Gazet JC, Ford HT, Gray R, McConkey C, Sutcliffe R, Quilliam J et al. Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy. Ann Oncol 2001; 12: 685-691.
22. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001; (30): 96-102.
23. Cleator SJ, Makris A, Ashley SE, Lal R, Powles TJ. Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival. Ann Oncol 2005; 16: 267-272.
24. Semiglazov VF, Topuzov EE, Bavli JL, Moiseyenko VM, Ivanova OA, Seleznev IK et al. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol 1994; 5: 591-595.
25. Danforth DN Jr, Cowan K, Altemus R, Merino M, Chow C, Berman A. Preoperative FLAC/granulocyte-colony-stimulating factor chemotherapy for stage II breast cancer: a prospective randomized trial. Ann Surg Oncol 2003; 10: 635-644.
26. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366: 2087-2106.
27. Jatoi I, Proschan MA. Randomized trials of breast-conserving therapy versus mastectomy for primary breast cancer: a pooled analysis of updated results. Am J Clin Oncol 2005; 28: 289-294.
28. Yeh E, Slanetz P, Kopans DB, Rafferty E, Georgian-Smith D, Moy L et al. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. AJR Am J Roentgenol 2005; 184: 868-877.
29. Rosen EL, Blackwell KL, Baker JA, Soo MS, Bentley RC, Yu D et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJR Am J Roentgenol 2003; 181: 1275-1282.
30. von Minckwitz G, Blohmer JU, Raab G, Lohr A, Gerber B, Heinrich G et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 2005; 16: 56-63.
31. Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006; 24: 2019-2027.
32. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002; 20: 1456-1466.
33. George SL. Response rate as an endpoint in clinical trials. J Natl Cancer Inst 2007; 99: 98-99.
34. Jones RL, Smith IE. Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response. Lancet Oncol 2006; 7: 869-874.
35. Kuerer HM, Hunt KK. The rationale for integration of lymphatic mapping and sentinel node biopsy in the management of breast cancer patients receiving neoadjuvant chemotherapy. Semin Breast Dis 2002; 5: 80-87.
36. Xing Y, Foy M, Cox DD, Kuerer HM, Hunt KK, Cormier JN. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg 2006; 93: 539-546.
37. Purushotham AD, Upponi S, Klevesath MB, Bobrow L, Millar K, Myles JP et al. Morbidity after sentinel lymphnode biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol 2005; 23: 4312-4321.